MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Plicamycin

CAS No. : 18378-89-7

MCE 国际站：Plicamycin

产品活性：Plicamycin 是一种选择性和特异性地 Sp1 转录因子抑制剂。Plicamycin 通过降低 Sp1 蛋白表达来抑制癌细胞生长。

研究领域：Cell Cycle/DNA Damage  |  Anti-infection

作用靶点：DNA/RNA Synthesis  |  Bacterial  |  Antibiotic

In Vitro: Plicamycin (Mith) decreases Sp1 protein by inducing proteasome-dependent degradation, thereby suppressing cervical cancer growth through a DR5/caspase-8/Bid signaling pathway. Plicamycin inhibits HEp-2 and KB cell growth in a concentration-dependent manner after 48 h. Apoptotic cell death is qualitatively estimated by DAPI staining for nuclear condensation and fragmentation. Plicamycin leads to significant DNA fragmentation compared to untreated controls.

In Vivo: The antitumorigenic activity of Plicamycin (0.2 mg/kg/day) is determined in a xenograft model and observed reduction in tumor volume and weight. No significant mouse body weight loss is observed in Plicamycin-treatment groups, indicating that Plicamycin-associated toxicity is minimal. Plicamycin also increases TUNEL-positive cells in tumor xenografts. No notable intergroup differences are observed among organs, indicating no marked signs of systemic toxicity at the Plicamycin dose used in this study.

相关产品：Covalent Screening Library Plus  |  Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Anti-Infection Compound Library  |  Cell Cycle/DNA Damage Compound Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  Anti-Aging Compound Library  |  Drug Repurposing Compound Library  |  Covalent Screening Library  |  Antibacterial Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Antibiotics Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Food-Sourced Compound Library   |  Targeted Diversity Library  |  FDA-Approved Anticancer Drug Library  |  Human Metabolite Library  |  Withdrawn Drug Compound Library  |  Off-patent Drug Library  |  Highly Selective Inhibitors Library  |  Myricetin 3-O-α-L-arabinopyranoside  |  (1R,2S,7R)-Sitafloxacin-d₄ hydrochloride  |  Nebacumab  |  Doxorubicin-¹³C,d₃ TFA  |  Gepotidacin  |  Amycolatopsin A  |  Antibiotic A-33853  |  Estradiol hemihydrate  |  Sulbactam-d₂ sodium  |  IBU-DC Phosphoramidite  |  Antimicrobial agent-5  |  NBTIs-IN-4  |  Proanthocyanidins  |  Anticancer agent 120  |  Azlocillin sodium salt  |  Antitubercular agent-13  |  2,4-D sodium salt  |  Thailanstatin D  |  Toyocamycin  |  Lenampicillin hydrochloride  |  Hispolon  |  PC58538  |  Carboplatin-d₄  |  SPR206 acetate  |  Caracemide  |  Antimicrobial agent-10  |  Doxycycline calcium  |  Farudodstat  |  Antibacterial agent 138  |  Staurosporine

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物  |  寡核苷酸  |  抗体  |  点击化学

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。